AM-Pharma B.V., a biopharmaceutical company focused on the development
of recAP (recombinant human Alkaline Phosphatase) for inflammatory
indications, announces that the American Journal of Kidney Disease has
published an In Translation feature entitled: Alkaline
phosphatase: a possible new treatment option for sepsis-associated acute
kidney injury in critically ill patients.
AJKD's In Translation is a recurring education feature that is an
authoritative review of science with diagnostic or therapeutic
implications in clinical practise in nephrology. The authors of the
article, (abstract available at: http://www.ajkd.org/article/S0272-6386(13)01636-3/abstract)
are from Professor Pickkers' group, at the Department of Intensive Care
Medicine, Nijmegen Institute for Infection, Inflammation and Immunity,
Radboud University Nijmegen Medical Centre, The Neherlands.
He and his affiliates discuss the multi-factorial pathogenesis of
sepsis-associated Acute Kidney Injury (AKI) and note that to be truly
successful, an intervention would also need to address not a single but
They concluded that: "AP seems to be a promising new therapy for
patients with sepsis-associated AKI because it restores an endogenously
expressed protective enzyme that appears to exert a dual mechanism of
action. AP may prevent the effects of inflammation and hypoxia, key
events in the pathogenesis of sepsis-associated AKI. Therefore, AP seems
to be a potent new treatment option for these patients."
The authors also noted that: "As inflammation and hypoxia are also
involved in AKI induced by several other causes, including cardiac
surgery and trauma, it would be of interest to further examine the
therapeutic effects of AP in these additional clinical circumstances."
Commenting on the review paper, Erik van den Berg, CEO of AM-Pharma
said, "It is satisfying and reassuring that an independent research
group has come to similar conclusions to our research, on the potential
of Alkaline Phosphatase to treat patients with a variety of AKI. We look
forward to presenting further data on the clinical trials with recAP."
Notes for Editors
About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and
clinical development of Alkaline Phosphatase as protective treatment of
acute kidney injury and inflammatory bowel diseases. AM-Pharma is based
in Bunnik, The Netherlands. Based on the strong results of the Phase II
trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a
Phase II trial in Ulcerative Colitis - a form of inflammatory bowel
disease - AM-Pharma developed an innovative recombinant form of human
Alkaline Phosphatase. This recombinant Alkaline Phosphatase will be used
in future trials and for commercialization. AM-Pharma raised €29.2M in
Q4 2011, enabling AM-Pharma to finalize the GMP production and the
development through phase II.
- ENDS -
[ Back To NFVZone's Homepage ]